Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers — De Clercq Erik (2010) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers
Shared by
De Clercq Erik
KU Leuven
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers
Article
2010
en
Authors
De Clercq Erik
KU Leuven
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2005
Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100
De Clercq Erik
Article
2009
The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)
De Clercq Erik
Article
2001
AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-γ Receptor-Deficient Mice
Patrick Matthys
,
Sigrid Hatse
,
Kurt Vermeire
,
Anja Wuyts
,
Gary Bridger
,
Geoffrey Henson
,
De Clercq Erik
,
Alfons Billiau
,
Dominique Schols
Article
2016
Recent Insights and Advances in the Management of Merkel Cell Carcinoma
Patricia Banks
,
Shahneen Sandhu
,
David Gyorki
,
Meredith Johnston
,
Danny Rischin
Article
2017
Recent advances for measurement of protein synthesis rates, use of the ‘Virtual Biopsy’ approach, and measurement of muscle mass
Marc Hellerstein
,
William J. Evans
Discussion(0)
No comments yet. Be the first to comment.